This Solicitation opportunity from Department Of Defense was posted on May 20, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
DIPHENHYDRAMINE HYD
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The contract solicitation SPE2DP-26-T-3498 calls for the procurement of 2 packages of DIPHENHYDRAMINE HYDROCHLORIDE CAPSULES, each containing 100 units, identified by NSN 6505-00-132-0294 and requiring compliance with U.S. Pharmacopeia standards at 25 mg per unit. The product must be supplied by approved manufacturers including MARLEX PHARMACEUTICALS INC, RICHMOND PHARMACEUTICALS INC, and DIXON-SHANE LLC, each identified by their respective NDC codes. The item is classified as a TYPE I (CODE M) drug with a non-extendable 24-month shelf life and must be packaged in sealed unit containers that protect against damage and breakage, with outer shipping containers suitable for safe transport at the lowest cost to the destination. All packaging and marking must strictly adhere to the Medical Marking Standard No. 1, which supersedes MIL-STD-129, and palletization must follow DLA Packaging Requirements for Procurement. The material is not considered hazardous under FED-STD-313 and must be commercially packaged per ASTM D3951, although DLA’s Master List of Technical and Quality Requirements takes precedence over any commercial standards. Delivery is required FOB destination within 10 days of the award to Rose Barracks, Vilseck, Germany, with inspection and acceptance also occurring at the destination. The solicitation mandates complete compliance with federal and defense regulations including the Buy American Act and Berry Amendment, and suppliers must meet cybersecurity, ethical, and employment obligations under applicable FAR and DFARS clauses. All contractors must maintain a current SAM registration, provide accurate entity identifiers and CAGE codes, and submit quotations exclusively through the DLA Internet Bid Board System by the deadline of May 26, 2026. Payment processing must utilize the Wide Area Workflow system with required documentation including invoices and receiving reports. The procurement is not a small business set-aside, and all bids must include full representation of socioeconomic status, exclusion status, and compliance with trafficking and employment eligibility certification requirements.
General Info
Agency
NAICS
Place of Performance
USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
DIPHENHYDRAMINE HYDROCHLORIDE CAPSULES<(>,<)>
RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
APPLICABLE TO ALL MEDICAL ACQUISITIONS:
PACKAGING AND PACKING SHALL BE COMMERCIAL AS
SPECIFIED IN THE PROCUREMENT DOCUMENT.
EACH COMPLETE UNIT SHALL BE PROPERLY PACKAGED
IN A SUITABLE SEALED UNIT CONTAINER CAPABLE
OF PROTECTING THE CONTENTS FROM DAMAGE AND/OR
BREAKAGE.
UNITS SHALL BE PACKED IN SUITABLE COMMERCIAL
EXTERIOR (SHIPPING) CONTAINERS (EXPORT WHEN
NECESSARY) WHICH SHALL INSURE ACCEPTANCE AND
SAFE DELIVERY BY COMMON OR OTHER CARRIER, AT
THE LOWEST RATE, TO POINT OF DELIVERY CALLED
FOR IN THE CONTRACT OR ORDER.
MATERIAL MUST BE MARKED IAW MEDICAL MARKING
STANDARD NO. 1. THIS SUPERCEDES ALL REFERENCES
TO MIL-STD-129.
COPIES OF MEDICAL MARKING STANDARD NO. 1
(MMS NO. 1) MAY BE OBTAINED BY CONTACTING DLA
TROOP SUPPORT VIA EMAIL TO fssb@dla.mil. MMS NO. 1 IS ALSO AVAILABLE ONLINE AT: https://www.dla.mil/Logistics-Operations/Packaging/
RD003, COVERED DEFENSE INFORMATION POTENTIALLY APPLIES
RA001: THIS DOCUMENT INCORPORATES TECHNICAL AND/OR QUALITY REQUIREMENTS
(IDENTIFIED BY AN 'R' OR AN 'I' NUMBER) SET FORTH IN FULL TEXT IN THE
DLA MASTER LIST OF TECHNICAL AND QUALITY REQUIREMENTS FOUND ON THE WEB
AT:
http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx
FOR SIMPLIFIED ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE SOLICITATION ISSUE DATE OR THE AWARD DATE CONTROLS. FOR LARGE ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE RFP ISSUE DATE APPLIES UNLESS A SOLICITATION AMENDMENT INCORPORATES A FOLLOW-ON REVISION, IN WHICH CASE THE AMENDMENT DATE CONTROLS.
RQ011: REMOVAL OF GOVERNMENT IDENTIFICATION FROM NON-ACCEPTED SUPPLIES
USP,25 MG,UNIT DOSE,100S
U/I "PG" (100S)
MARLEX PHARM NDC 10135-0166-13
RICHMOND PHARM NDC54738-0115-13
MAJOR NDC 00904-5306-61
FSAB BCHAMBERLIN 08050
This device or drug is regulated by the FDA. Note to Buyers: The contracting official shall send a referral in EBS to the product specialist for confirmation.
SPE2DP-26-T-3498
SECTION B
Please include bidder name and bidder contact information, manufacturer name, manufacturer part number, and item description.
1 PG = 100 EA RS016: Shelf-life requirement RS001 for a TYPE I (CODE M) item with a shelf life of 24 months (non-extendable) applies to this item.
SHALL BE MARKED IAW THE LATEST EDITION OF
THE MEDICAL MARKING STANDARD NO. 1.
MMS NO. 1 IS AVAILABLE ONLINE AT:
https://www.dla.mil/Logistics-Operations/Packaging/
MARLEX PHARMACEUTICAL 03KJ7 P/N NDC10135-0166-13 MARLEX PHARMACEUTICALS INC 1TAP7 P/N NDC10135-0166-13 DIXON-SHANE LLC 5J522 P/N NDC17236-0516-01 RICHMOND PHARMACEUTICALS, INC. 0WZB6 P/N NDC54738-0115-13
DLA issues this document using the DoD authorized unit of issue, please refer to the following URL to determine the corresponding ANSI X12 unit of issue.
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.dla.mil%2FPortals%2F104%2FDocuments% 2FDLMS%2FeApplications%2FLogDataAdmin%2FUnitofIssueandPurchaseUnit.xlsx&wdOrigin=BROWSELINK
CLIN PR PRLI UI QUANTITY UNIT PRICE TOTAL PRICE.
0001 7016859782 0001 PG 2.000
NSN/MATERIAL:6505001320294
DELIVERY (IN DAYS):0010
DELIVER FOB: DESTINATION
QTY VARIANCE: PLUS 0% MINUS 0%
INSPECTION POINT: DESTINATION
ACCEPTANCE POINT: DESTINATION
PREP FOR DELIVERY:
PKGING DATA-QUP:001
IF MATERIAL IS CONSIDERED HAZARDOUS IAW FED-STD-313,
PACKAGE IN ACCORDANCE WITH TQ REQUIREMENT IP025.
IF THE MATERIAL IS NOT CONSIDERED HAZARDOUS, IN ACCORDANCE WITH
FED-STD-313, THE MATERIAL SHALL BE COMMERCIALLY PACKAGED IN ACCORDANCE
WITH ASTM D3951.
All DLA Master List of Technical and Quality Requirements take precedence over ASTM D3951. Mark and label all packaging and packing in accordance with MIL-STD-129. The Unit of Issue (U/I) and Quantity per Unit Pack (QUP) will be as specified in the contract/purchase order. PALLETIZATION SHALL BE IN ACCORDANCE WITH RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
BULK BREAK POINT:
W81X9C
0002 CS BN CO A DISTRIBUTI
SPE2DP-26-T-3498
SECTION B
PR: 7016859782 PRLI: 0001 CONT’D
ROSE BARRACKS BLDG 728 AWCF SSF
SUDLAGER STRASSE
VILSECK 92249
DE
FOR TRANSPORTATION SEE DLAD DLAD PROC NOTE C19. FOR FIRST DESTINATION TRANSPORTATION SEE DLAD PROC NOTE
C20 AND CONTRACT
FREIGHT SHIPPING ADDRESS:
W81X9C
0002 CS BN CO A DISTRIBUTI
ROSE BARRACKS BLDG 728 AWCF SSF
SUDLAGER STRASSE
VILSECK 92249
DE
MARKFOR
W81X9C
0002 CS BN CO A DISTRIBUTI
ROSE BARRACKS BLDG 728 AWCF SSF
SUDLAGER STRASSE
VILSECK 92249
DE
M/F: (TCN) W81X9C61390132
RDD: 150
PROJ: 9GU TP 3
SUPP ADD: W9046W SIG: C
FOR GOVERNMENT USE ONLY: (IPD) 12
DIC: A01 DIST: V ADV: 2A FC: Z9
Need Ship Date:00/00/0000 Original Required Delivery Date:05/22/2026
SPE2DP-26-T-3498 NSN/Part Number: 6505-00-132-0294 Quantity: 2 PG Purchase Request: 7016859782QTY: 2 Delivery: 10 days ADO
More opportunities from Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS